Relmada Therapeutics Inc. is a clinical-stage biotechnology company dedicated to creating novel versions of drug products to address unmet medical needs in treating central nervous system diseases, with a primary focus on developing esmethadone, an NMDA receptor antagonist. Esmethadone, the lead product candidate, is an oral agent designed for treating depression and other potential indications.